Cabometyx 40 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FCYY4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,822
Award facts
- Contract value 100% obligated
- $16,822.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $16,822.18 to DMS Pharmaceutical Group Inc. for 30 tablets of Cabometyx 40 mg, an oncology medication used to treat advanced renal cell carcinoma and hepatocellular carcinoma. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by December 1, 2025, and will be fulfilled from the company's Park Ridge facility.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling and completion date of December 31, 2036. The PPV-G GEN V contract positions DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3 billion acquisition strategy designed to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. As a critical supplier within the federal pharmaceutical supply chain since 2001, the company has demonstrated substantial performance across diverse therapeutic categories and product lines supporting military medical operations.
Quick answers
Who was awarded contract SPE2DR26FCYY4?
SPE2DR26FCYY4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 28, 2025.
How much is contract SPE2DR26FCYY4 worth?
The government has obligated $16,822 on SPE2DR26FCYY4.
Is contract SPE2DR26FCYY4 an order under another contract?
Yes. SPE2DR26FCYY4 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCYY4 competed?
The extent of competition for SPE2DR26FCYY4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award